Latus Bio raised $97 million to advance its pipeline of AAV gene therapies for the treatment of central nervous system diseases, including Huntington’s disease and CLN2 disease, both rare disorders.
Latus Bio raised $97 million to advance its pipeline of AAV gene therapies for the treatment of central nervous system diseases, including Huntington’s disease and CLN2 disease, both rare disorders.